

Seminar

Discovery of a Novel Incretin Analogue GL0034

Rajamannar Thennati

**Sun Pharmaceutical Industries Ltd.,
Vadodara**

Glucagon-like peptide-1 receptor agonists (GLP-1RA) provide substantial reductions in HbA1c and significant body weight loss in patients with type 2 diabetes (T2D). Semaglutide and Tirzepatide are approved therapies for the treatment of Type 2 Diabetes and Obesity.

A novel incretin analogue, GL0034 (Utreglutide) with potent agonist activity on glucagon-like peptide-1 (GLP-1R) receptor is in clinical program. Phase 1 study in individuals with obesity were evaluated, GL0034 pharmacodynamic effects show potential for type 2 diabetes and obesity disorders.

Wednesday, Feb 28th 2024

11:30 Hrs (Tea / Coffee 11:15 Hrs)

Auditorium, TIFR-H